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AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) IN UNTREATED
FIRST RELAPSE (REL1) OR FOLLOWING RE-INDUCTION CHEMOTHER-
APY (CT) FOR PATIENTS (PTS) WITH ACUTE MYELOGENOUS LEUKE-
MIA (AML)
Pornvipavee, R.; Dierkhising, R.A.; Elliott, M.A.; Hogan, W.J.; Kre-
mers, W.K.; Letendre, L.; Pedersen, R.A.; Tefferi, A.; Litzow, M.R.
Mayo Clinic College of Medicine, Rochester, MN.
The timing of ASCT for AML after ﬁrst relapse is controversial.
The purpose of this study was to review our results in AML pts in
ﬁrst relapse by comparing outcomes between pts taken directly to
ASCT and pts receiving re-induction chemotherapy prior to
ASCT. Between January 1990 and March 2003, 37 pts with AML
in REL1 or CT underwent ASCT. Survival was analyzed using the
Kaplan-Meier (KM) methodology with statistical comparisons us-
ing the log-rank test. Univariate predictors of survival were exam-
ined using Cox proportional hazard models. Of the 37, 25 and 12
pts underwent ASCT at CT and REL1 (median age 46 vs 42 years),
respectively. There was only 1 pt in the CT group who had
refractory disease. In the CT group, 18 pts (72%) and 7 pts (28%)
had stem cells harvested during CR1 and CR2, respectively. In the
REL1 group, all pts had stem cells harvested in CR1. Thirty of 37
pts received cyclophosphamide and total body irradiation (Cy/
TBI) for conditioning and the remainder received busulfan and
cyclophosphamide (Bu/Cy). There were no statistically signiﬁcant
differences in the baseline characteristics between the two groups.
The percentage of bone marrow blasts at ﬁrst relapse was increased
in the CT versus the REL1 group (median 40% vs 15%, p0.06).
KM analysis showed that there was no signiﬁcant difference be-
tween the two groups in time to neutrophil and platelet engraft-
ment. The REL1 group had a signiﬁcantly shorter time to relapse
than CT. The CT group had signiﬁcantly higher DFS than REL1
and a trend toward better OS with no difference in TRM. The
Table details estimated probabilities of these endpoints. Univariate
Cox proportional hazard analysis for overall survival showed that
younger age at diagnosis and transplantation, unfavorable cytoge-
netic abnormalities at diagnosis and relapse were signiﬁcantly as-
sociated with a higher risk of death. Higher percentage of blasts in
bone marrow at ﬁrst relapse and shorter duration of CR1 were not
signiﬁcantly associated with death. In a multivariate model, only
unfavorable cytogenetic abnormalities at ﬁrst relapse were signif-
icantly associated with an increase risk of death. Although OS
between CT and REL1 groups was not signiﬁcantly different, the
time to relapse and DFS were signiﬁcantly longer for the CT
group. Although retrospective and limited by selection bias, this
study suggests that there may be an advantage for re-induction
chemotherapy for AML in ﬁrst relapse before ASCT.
REL1
Post
CT
p
value*
Probability of Relapse (%) 0.0075
1 year 83.3 45.8
5 years 83.3 59.9
Median time to relapse (mos) 6.1 13.7
Overall Survival (OS) (%) 0.09
1 year 41.7 68.0
5 years 8.3 40.8
Median time of OS (mos) 8.7 17.9
Disease free survival (DFS) (%) 0.006
1 year 16.7 52.0
5 years 8.3 39.0
Median time of DFS (mos) 6.1 13.7
Transplant related mortality (TRM) (%) 0.50
1 year 0 4.0
*Log rank test comparing distribution of event times over multiple
comparisons.
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HIGH AVIDITY CYCLIN E1-DERIVED PEPTIDE-SPECIFIC CTL KILL LYM-
PHOID LEUKEMIA CELLS AND CROSS-RECOGNIZE A HOMOLOGOUS
CYCLIN E2-DERIVED PEPTIDE
Kondo, Y.; Wieder, E.; Lu, S.; Molldrem, J.J. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
Using a similar strategy that was used to identify PR1 as a
leukemia-associated antigen (LAA), we identiﬁed two homologous
HLA-A2-restricted peptides from cyclin E1 (CCNE1M) and cy-
clin E2 (CCNE2L) that could be used to elicit peptide-speciﬁc
CTL from healthy donors. The two peptides differ by a single
amino acid at position 7 and have equal binding afﬁnity for HLA-
A2, and each elicited peptide-speciﬁc CTL with equal efﬁciency.
Because each CCNE1M- and CCNE2L-CTL clone, derived from
limiting dilution, cross-recognized the other homologous peptide,
we hypothesized that each clone would efﬁciently kill leukemia that
over-expressed either or both CCNE1 and CCNE2 proteins.
Sorted high avidity CTL showed higher speciﬁc lysis of peptide-
pulsed T2 than did low avidity CTL (38.8% vs 31.9% speciﬁc lysis,
respectively, at E:T 10:1, p  0.02). The ﬂuorescence decay of
tetramer dissociation (ln (peptide/HLA-A2 tetramer)) over time
was linear for each clone, showing that avidity was proportional to
TCR afﬁnity and tetramer dissociation t1/2 was determined based
on ﬁrst order kinetics. CCNE1M-CTL had higher afﬁnity for
CCNE1M/HLA-A2 (CCNE1/A2, t1/284.5 min; CCNE2/A2,
t1/225.3 min) and preferentially killed CCNE1M-pulsed T2
cells (CCNE1, 56.9% vs CCNE2, 38%, respectively, at E:T 10:1).
CCNE2L-CTL also had higher TCR afﬁnity for CCNE1M/
HLA-A2 (CCNE1/A2, t1/229.5 min; CCNE2/A2, t1/210.7
min), but showed only slightly higher speciﬁc lysis of CCNE1M-
pulsed T2 cells (CCNE1, 49.3% vs CCNE2, 44.2% speciﬁc lysis,
respectively, at E:T 10:1). Each clone speciﬁcally lysed HLA-A2
T-ALL leukemia cells in proportion to both CCNE1 and CCNE2
protein overexpression (CCNE1M-CTL, R20.89; CCNE2L-
CTL, R20.88) in an HLA-A2-restricted manner. Both the high
and low afﬁnity clones showed equal lysis of T-ALL cells that
expressed large amounts of each protein (CCNE1M-CTL, 24.3%
vs CCNE2L-CTL , 23.8%, at E:T 10:1). However, high afﬁnity
CCNE1M-CTL killed T-ALL cells signiﬁcantly better than low
afﬁnity CCNE2L-CTL (16.8% vs 6.6% lysis, respectively, at E:T
10:1) when the T-ALL expressed a 2.5-fold lower amount of both
CCNE1 and CCNE2 proteins. We conclude that the CCNE1M
and CCNE2L homologous self-peptides are lymphoid LAA. Fur-
thermore, while the higher TCR afﬁnity of CCNE1M-CTL sug-
gests that the CCNE1M peptide is the more dominant epitope,
ultimate target susceptibility is enhanced due to degeneracy of the
resulting CTL clones against homologous peptide epitopes.
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NON-MYELOABLATIVE CONDITIONING FOR ALLOGENEIC HEMATOPOI-
ETIC STEM CELL TRANSPLANTATION IN PATIENTS WITH ACUTE MY-
ELOID LEUKEMIA. THE IMPACT OF THE REMISSION STATUS
Gutierrez-Aguirre, C.H.; Cantu-Rodriguez, O.G.; Gonzalez-LLano,
O.; Salazar-Riojas, R.; Martinez-Gonzalez, O.L.; Jaime-Perez, J.C.;
Gomez-Almaguer, D. Hospital Universitario Dr. Jose´ E. Gonza´lez,
U.A.N.L., Monterrey, Nuevo Leo´n, Mexico.
Background: Multicentre randomized trials have shown that
allogeneic hematopoietic stem cell transplantation (HSCT) is the
most effective strategy for preventing relapse in patients in ﬁrst
complete remission (CR) of acute myeloblastic leukemia (AML),
offering up to 50% disease-free survival. However in adult patients
with good risk AML, allogeneic HSCT is usually indicated in
second complete remission or ﬁrst untreated relapse. We analyzed
the outcome of 16 AML patients who received a reduced intensity
conditioning regimen for allogeneic HSCT in ﬁrst or second
remission. Patients and Methods: Sixteen AML patients (1 M1, 8
M2, 3 M3, 2 M4 and 2 M5), 9 in ﬁrst CR (FCR) and 7 in second
CR (SCR) were included. All patients received Busulfan 4 mg/kg/
d/2 days, Fludarabine 30 mg/m2/d/3 days and cyclophosphamide
350 mg/m2/d/3 days as conditioning regimen. The median age was
32 years (range 3–56) in both groups. The source of hematopoietic
stem cells (HSC) was peripheral blood and donors were HLA
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matched siblings in all instances. The median number of CD34
cells infused was 5.2  106/kg in both groups. All patients received
cyclosporine and methotrexate as GvHD prophylaxis. Eleven pa-
tients (68%) were transplanted as an outpatient. Results: The
range of follow-up from date of transplantation was 4–60 months.
All patients showed myeloid engraftment (neutrophils 0.5 
109/l) after a median of 15 days, and platelet recovery 20  109/l
was achieved after a median of 13 days. Acute GVHD was observed
in 7 (43.7%) patients and chronic GVHD in 8 (50%) patients,
without signiﬁcant differences in both groups. The relapse inci-
dence and mortality for the 9 patients who were transplanted in
FCR was 22%, and for patients transplanted in SCR was 85%.
Death occurred because of relapse in all cases. Conclusions: Our
data show that reduced-intensity conditioning and allogeneic
HSCT can induce stable remission in AML patients transplanted
in FCR. More studies are needed to determine the role of non-
myeloablative conditioning and transplantation in patients with
refractory or relapsing AML.
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HEMATOPOIETIC CELL TRANSPLANTATION FROM UNRELATED AND
RELATED DONORS AFTER A FLUDARABINE-ALKYLATOR-BASED REGI-
MEN IS A REASONABLE TREATMENT OPTION FOR OLDER PATIENTS
(>60 YEARS) WITH ACTIVE HEMATOLOGIC MALIGNANCIES
Finke, J.; Spyridonidis, A.; Ihorst, G.; Gruellich, C.; Zeiser, R.; Bertz,
H. Department of Hematology & Oncology, Freiburg University Medical
Hospital, Freiburg, Germany.
The upper age limit for allogeneic hematopoietic cell transplan-
tation (aHCT) used to be in the range of 50 to 55 years, well below
the age with the highest incidence of myeloid malignancies. Here
we present retrospective data on 69 consecutive patients (pts) older
than 60 years of age (median 64; range 60–74) transplanted from a
matched sibling (n20) or unrelated (n49) donor after condi-
tioning with a uniform, dose-adapted, myeloablative conditioning
regimen consisting of ﬂudarabine 150 mg/m2, carmustine 300
mg/m2 and melphalan 110 mg/m2 (FBM). GvHD prophylaxis
consisted of cyclosporine A and mycophenolate mofetil with addi-
tional rabbit anti-T lymphocyte globulin (ATG) in the unrelated
setting. Apart from 5 pts. receiving marrow all other pts received
ﬁlgastrim mobilized peripheral blood grafts (PBHCT). Pts pre-
sented with CLL (3), follicular NHL (2), mantle cell NHL (2),
multiple myeloma (1), myeloproliferative syndrome (3), MDS-RA
(3) and AML or MDS-RAEB (n55). Apart from 3 pts in CR1 and
3 in CR2, all other had active disease, either refractory or un-
treated. Acute GvHD II° occurred in 10 related (50%) and 16
unrelated (45%) transplanted pts. In the related transplantations, 6
pts died due to TRM (30%) and 4 due to relapse (20%). Causes of
death were infections (4 pts), acute GvHD (1 pt) and infection in
the context of chronic GvHD (1 pt). In the unrelated transplanta-
tions, there were 8 deaths due to TRM (16%) and 6 due to relapse
(12%). Causes of death after unrelated aHCT were graft failure (1
pt), ARDS (1 pt), infections (4 pts), acute GvHD (1 pt) and
myocardial infarction (d 230 after aHCT, 1 pt). After a median
follow up of approx. 1 year (range 3–1778 days), the estimated
probability of overall survival was 46% and 61% for related and
unrelated transplantations, respectively. This difference was not
statistically signiﬁcant. We conclude, that aHCT using the dose-
adapted FBM protocol is a reasonable treatment option for pts
older than 60 years of age with high risk lympho-hematologic
malignancies. In contrast to previous reports from transplant reg-
istries, we found that aHCT from unrelated donors incorporating
in vivo ATG results in outcomes comparable to HCT from related
donors. We suggest that the lack of HLA identical relatives in
older pts should not discourage the transplant choice.
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DYSREGULATION OF THE 	
 T CELL REPERTOIRE IN PATIENTS WITH
ACUTE LEUKEMIA: IMPLICATIONS FOR CELLULAR IMMUNOTHERAPY
Lamb, L.S. University of Alabama at Birmingham, Birmingham, AL.
Introduction: Despite their relatively small numbers,  T
cells have signiﬁcant innate anti-tumor activity. This is princi-
pally due to their ability to respond, without prior exposure or
priming, to a broad array of stress-associated antigens com-
monly displayed on malignant cells. Our laboratory has shown
increased allogeneic  T cells to have a protective effect against
relapse in patients transplanted for leukemia, and that  T cells
are not associated with increased risk of graft versus host disease
in these patients. In order to gain insight into the nature of a
potential antileukemic effect of  T cells, we sought to deter-
mine if evidence existed for an autologous  T cell immune
response in pre-treatment leukemia patients. Methods: We ﬁrst
examined the  T cell receptor (TCR) phenotype and comple-
mentarity determining region 3 (CDR3) cDNA sequence from
17 leukemia patients and 3 healthy controls to determine the 
TCR repertoire and clonality. Following this, we cultured  T
cells from healthy ﬁrst degree relatives with the corresponding
patients’ primary leukemic blasts. We then examined  T cell
proliferation and TCR repertoire at weekly intervals and cyto-
toxicity to patient blasts after 3–4 weeks of culture and com-
pared these results with co-cultures of  T cells from healthy
volunteers and normal allogenic mononuclear cells (MNC).
Results: All patients and healthy volunteers had normal abso-
lute  T cell counts. In 15/17 patients, V1  T cells were
predominant, in contrast to V2 predominance in healthy
volunteers. V1 CDR3-region cDNA sequence analysis re-
vealed that leukemia patients exclusively used the J1 constant
region, with healthy controls showing both J1 and J2 use.
Two patients with APL showed signiﬁcant CDR3 conservation
as did one B-ALL and one T-ALL patient. When fresh alloge-
neic  T cells were cultured with primary patient blasts, V2
T cells were quickly deleted and V1 T cells proliferated and
in 4 instances were able to lyse primary blasts. Insigniﬁcant 
T cell proliferation was observed in cultures with normal MNC.
Conclusions: These ﬁndings point to a complex dysregulation
in the  T cell compartment in leukemia patients including
deletion of the V2 subtype in vitro and in vivo and a V1 T
cell response to leukemia in vivo. These ﬁndings suggest con-
sideration of allogeneic  T cell therapy as part of a compre-
hensive immunotherapeutic strategy for acute leukemia.
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GEMTUZUMAB-OZOGAMICIN (GO; MYLOTARG) AS PART OF CONSOL-
IDATION THERAPY FOR AML BEFORE AUTOGRAFT: LOW INCIDENCE
OF HEPATIC VENO-OCCLUSIVE DISEASE
Fernandez, H.F.1; Kim, H.T.2; Bennett, J.M.3; Dewald, G.4; Talllman,
M.S.5; Lazarus, H.M.6 1. University of Miami, Miami, FL; 2. Dana
Farber Cancer Institute, Boston, MA; 3. University of Rochester, Roch-
ester, NY; 4. Mayo Clinic, Rochester, MN; 5. Northwestern University,
Chicago, IL; 6. University Hospitals of Cleveland, Cleveland, OH.
Background: Gemtuzumab-Ozogamicin (GO) has been used
successfully in induction therapy for de novo acute myeloid
leukemia (AML). Several reports note a high incidence of he-
patic veno-occlusive disease (VOD) when given within 115 days
of transplant, particularly in allogeneic transplant recipients.
Data are limited in the autologous transplant setting. Methods:
In an ongoing ECOG (E1900) study for de novo AML in patients
less than 61 years of age, GO was given as consolidation therapy
to 23 patients median (range) age 51 (21–59) years who achieved
complete remission after induction with cytarabine 100 mg/m2/
day CI over 7 days plus daunorubicin 45–90 mg/m2/day for 3
days. Two separate consolidations then were given using cytar-
abine 3 g/m2  6 doses. Upon recovery from the second cycle,
patients were given one dose of GO 6 mg/m2. Upon recovery of
blood counts after GO, patients underwent an autotransplant
conditioning regimen of IV busulfan 0.8 mg/kg  16 doses and
cyclophosphamide 60 mg/kg  2 doses with autologous blood
stem cell support. Results: One patient developed VOD after
the administration of GO but fully recovered without further
sequelae. The remaining 22 patients have proceeded to trans-
plant. All have engrafted after their procedure with no patient
experiencing VOD within 100 days post-transplant. Conclu-
sion: GO is a safe consolidation approach in younger AML
patients with less than 5% developing VOD with its use when
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